CORRECTED: Par Pays $100M To Settle Suit Over Generic Heartburn Drug
Par Pharmaceutical Cos. has agreed to pay $100 million to Salix Pharmaceuticals Inc. unit Santarus Inc. and the University of Missouri to resolve claims Par's generic version of the heartburn drug...To view the full article, register now.
Already a subscriber? Click here to view full article